real-time news and commentary for investors
Tuesday, Oct 30
2012, 11:23 AM
More on Impax Laboratories (IPXL): Q3 misses on all fronts due to higher-than-anticipated...
More on Impax Laboratories (IPXL): Q3 misses on all fronts due to higher-than-anticipated acquisition costs, and litigation expenses associated with the voluntary withdrawal of one of its generic products from the market. Total revenue jumped 21% however, driven largely by better sales of Zomig, which was licensed from AstraZeneca (AZN). The Company also updated its FY12 financial outlook, now saying it expects total revenues for Q4 to decline by around 15% to 20% from Q3.